Adding a NOAC to aspirin ‘reduces events after revascularisation’
New results from the VOYAGER PAD trial shows a benefit with no increase in bleeds
Patients with symptomatic peripheral artery disease (PAD) undergoing leg revascularisation have fewer major adverse limb and cardiovascular events long-term if they take rivaroxaban as well as aspirin, researchers say.
The further analysis of results of the VOYAGER PAD trial was presented at ACC.21, the virtual annual meeting of the American College of Cardiology.
The primary results of the trial had shown that rivaroxaban plus aspirin reduced first events by 15% among patients with PAD after lower-extremity revascularisation.
The new analysis looked at the benefit of rivaroxaban on total (first and subsequent) events.
